Levetiracetam

# Levetiracetam ## Overview - **Classification**: Antiepileptic Drug (AED), Pyrrolidine derivative - **Mechanism**: Modulates synaptic vesicle glycoprotein 2A (SV2A) in the brain, affecting neurotransmitter release and neuronal excitability. ## Primary Indications 1. **Partial-onset seizures**: With or without secondary generalization in patients ≥1 month. 2. **Myoclonic seizures**: In patients ≥12 years with juvenile myoclonic epilepsy. 3. **Primary generalized tonic-clonic (PGTC) seizures**: In patients ≥6 years with idiopathic generalized epilepsy. ## Adult Dosing ### Standard Dosing **Partial-onset Seizures, Myoclonic Seizures, PGTC Seizures** - **Dose**: Initial **500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) or Intravenous (IV) - **Titration**: Increase by **500 mg** BID every 2 weeks - **Maximum Dose**: Up to **1500 mg** BID (**3000 mg/day**) ### Dose Adjustments - **Renal Impairment**: Adjust based on CrCl: - CrCl 50-79 mL/min: **500-1000 mg** BID - CrCl 30-49 mL/min: **250-750 mg** BID - CrCl <30 mL/min: **250-500 mg** BID - ESRD on dialysis: **250-500 mg** once daily, plus **250-500 mg** post-dialysis dose. - **Hepatic Impairment**: No specific adjustment for mild to moderate impairment. Monitor clinically. - **Elderly Patients**: Adjust based on renal function due to age-related decline. Start with lower doses. ## Pediatric Dosing ### Neonates (0-28 days) - **Indication**: Partial-onset seizures (off-label, often for status epilepticus). - **Dose**: Initial **7-10 mg/kg/dose** - **Frequency**: Every 12 hours (q12h) - **Titration**: Increase by **7-10 mg/kg/dose** every 2 days - **Maximum**: Up to **21-30 mg/kg/dose** q12h. Max **60 mg/kg/day**. - **Route**: IV (infusion over 15 min) or PO solution. - **Special Notes**: Doses are highly individualized; clinical monitoring is key. ### Infants (1-12 months) - **Indication**: Partial-onset seizures. - **Dose**: Initial **10 mg/kg/dose** - **Frequency**: Every 12 hours (q12h) - **Titration**: Increase by **10 mg/kg/dose** q12h every 2 weeks - **Maximum**: Up to **30 mg/kg/dose** q12h (max **60 mg/kg/day**). - **Route**: PO solution or IV. - **Formulation**: Oral solution (100 mg/mL) recommended for precise dosing. ### Children (1-12 years) - **Indication**: Partial-onset seizures. - **Dose**: Initial **10 mg/kg/dose** - **Frequency**: Every 12 hours (q12h) - **Titration**: Increase by **10 mg/kg/dose** q12h every 2 weeks - **Maximum**: Up to **30 mg/kg/dose** q12h (max **60 mg/kg/day**). - **Route**: PO solution/tablets or IV. - **Maximum Limit**: Do not exceed adult maximum dose of **3000 mg/day**. ### Adolescents (13-18 years) - **Indication**: Partial-onset, myoclonic, PGTC seizures. - **Dose**: Initial **500 mg** - **Frequency**: Twice daily (BID) - **Route**: PO or IV - **Maximum**: **3000 mg/day** (1500 mg BID). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to levetiracetam or any pyrrolidone derivative. ### Common Adverse Effects - **Very Common (>10%)**: Somnolence, asthenia, dizziness, headache, nasopharyngitis. - **Common (1-10%)**: Irritability, aggression, depression, anxiety, anorexia, nausea, diarrhea. - **Serious but Rare**: Suicidal ideation/behavior, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), angioedema, pancytopenia. ### Key Drug Interactions - **No significant CYP450 interactions**: Levetiracetam has a low potential for drug interactions. - **Methotrexate**: May reduce methotrexate clearance. Monitor methotrexate levels and for toxicity. - **Other CNS Depressants (e.g., alcohol, opioids)**: Increased risk of somnolence and dizziness. Use with caution. ## Monitoring & Follow-up - **Before Treatment**: Assess renal function (CrCl). No other routine baseline labs. - **During Treatment**: Monitor for CNS adverse effects (e.g., drowsiness, dizziness). Observe for behavioral/mood changes, especially in children. - **Clinical Signs**: Watch for worsening seizures, new skin rash, or signs of infection (rare blood dyscrasias). ## Clinical Pearls - 💡 **Titration**: Start low and titrate gradually to improve tolerability and reduce CNS side effects. - 💡 **Behavioral AEs**: Counsel patients/caregivers on potential for irritability, aggression, or mood changes, particularly in pediatric patients. - 💡 **Renal Adjustment**: Essential for renally impaired patients to prevent accumulation and toxicity. - 💡 **IV/PO Equivalence**: Levetiracetam has nearly 100% oral bioavailability, allowing for direct IV to PO conversion. - 💡 **No Routine Levels**: Therapeutic drug monitoring is generally not recommended due to predictable pharmacokinetics. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.